Evaluation of Novel Fetal Hemoglobin Inducer Drugs in Treatment of β-Hemoglobinopathy Disorders
Objective: The use of fetal hemoglobin (HbF) inducer drugs is considered as a novel approach in treatment of β-hemoglobinopathies, especially β- thalassemia and sickle cell disease. HbF inducers including hydroxyurea, histone deacetylase (HDAC) inhibitor agents such as sodium butyrate, azacitidine,...
Main Authors: | Fatemeh Salari, Mohammad Shahjahani, Seyed Ahmad Hosseini, Ali Dehghani Fard, Kaveh Jaseb |
---|---|
Format: | Article |
Language: | English |
Published: |
Tehran University of Medical Sciences
2013-07-01
|
Series: | International Journal of Hematology-Oncology and Stem Cell Research |
Subjects: | |
Online Access: | http://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/405/430 |
Similar Items
-
Evaluation of Novel Fetal Hemoglobin Inducer Drugs in Treatment of β-Hemoglobinopathy Disorders
by: Ali Dehghani Fard, et al.
Published: (2013-09-01) -
Blessing in disguise; a case of Hereditary Persistence of Fetal Hemoglobin
by: Irfan Shaukat, et al.
Published: (2018-11-01) -
Evaluation of Signaling Pathways Involved in γ-Globin Gene Induction Using Fetal Hemoglobin Inducer Drugs
by: Fakher Rahim, et al.
Published: (2013-07-01) -
Evaluation of Signaling Pathways Involved in γ-Globin Gene Induction Using Fetal Hemoglobin Inducer Drugs
by: Fakher Rahim, et al.
Published: (2013-09-01) -
β-Hemoglobinopathies: The Test Bench for Genome Editing-Based Therapeutic Strategies
by: Gloria Barbarani, et al.
Published: (2020-12-01)